Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.
The ability of heparin fractions of different molecular weight to potentiate the action of antithrombin III against the coagulation factors thrombin and Xa has been examined in purified reaction mixtures and in plasma. Residual thrombin and Xa have been determined by their peptidase activities against the synthetic peptide substrates H-D-Phe-Pip-Arg-pNA and Bz-Ile-Gly-Arg-pNA. High molecular weight heparin fractions were found to have higher anticoagulant activities than low molecular weight heparin when studied with both thrombin and Xa incubation mixtures in purified mixtures and in plasma. The inhibition of thrombin by heparin fractions and antithrombin III was unaffected by other plasma components. However, normal human plasma contained a component that inhibited the heparin and antithrombin III inhibition of Xa particularly when the high molecular weight heparin fraction was used. Experiments using a purified preparation of platelet factor 4 suggested that the platelet-derived heparin-neutralizing protein was not responsible for the inhibition.
D000818:Animals; D000990:Antithrombin III / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects; D002417:Cattle; D010450:Endopeptidases / Q000378:metabolism; D005170:Factor X / Q000037:antagonists & inhibitors*; D006493:Heparin / Q000494:pharmacology*; D006494:Heparin Antagonists; D006801:Humans; D008970:Molecular Weight; D009842:Oligopeptides / Q000378:metabolism
D006494:Heparin Antagonists; D009842:Oligopeptides; D000990:Antithrombin III; D005170:Factor X; D006493:Heparin; D010450:Endopeptidases